Clinflash Completes Series A Funding

Clinflash was founded in 2014, and further nominated as a national high-tech enterprise in 2018. The company developed a series of information system for clinical trials, including Clinflash EDC - Electronic Data Capture System, Clinflash IRT - Randomization and Trial Supply Management System and Clinflash Safety - Pharmacovigilance System. Clinflash systems were widely applied in large scale registration and post-market studies in China and global region, serving local and MNC customers for R&D of branded drugs, generics, medical devices, IVD, etc.

Clinflash enjoys an excellent reputation and is highly trusted by customers thanks to its in-depth industrial know-how, robust technology foundation and outstanding quality management system. Till now, Clinflash is cooperating with more than 300 leading healthcare companies and Clinical Research Organization (CRO) partners, providing systems and supporting services to 600+ clinical trial projects.

In areas of innovation drugs, Clinflash EDC and IRT support the successful completion of several phase III studies. Starting from 2018, nearly ten innovation drugs, which used Clinflash systems for pivotal studies, were approved for launch, or submitted new drug application (NDA) in China. Clinflash Safety is fully compiled by E2B R3 standard and chose by leading pharma and MedTech companies for Individual Case Safety Report (ICSR) submission as well as long term safety signal monitoring.

“The development of China and global clinical research needs the support of high-quality information system incorporated with leading mobile technology. Clinflash has strong R&D teams with leading clinical trial professionals and IT technologies. The company developed a series of high-standard clinical trial systems based on deep insight into unmet needs across different phases of clinical trials. Clinflash also aims to make continuous improvement of product quality with a focus on customer needs. We are pleased to invest in Clinflash. And we will work together to popularize Clinflash to the Asia Pacific and Global market,” said William Hu, Managing Partner at Qiming Venture Partners.

“Clinflash will extend business and coverage to leading R&D companies and CRO partners after series A funding. We will increase the investment in system development, technology and service team to continuously increase product quality and customer satisfaction, thereby helping our client improve R&D efficiency and reducing cost. Additionally, Clinflash will further extend the product portfolio with advanced technologies. Clinflash Clinical Trial Management System (CTMS) is estimated to be launched in this year, while Artificial Intelligence (AI) technologies will be introduced to current products, ” said by Gary Guan, General Manager of Clinflash.

About Clinflash

Founded in 2014, Clinflash is a leading provider of information solution and professional service in field of clinical development in China. Clinflash developed a series of systems for clinical trial projects, including Clinflash EDC - Electronic Data Capture System, Clinflash IRT - Randomization and Trial Supply Management System and Clinflash Safety - Pharmacovigilance System. Clinflash was nominated as a national high-tech enterprise in 2018 thanks to its leading technologies and patent portfolio. The company is cooperating with more than 300 leading local and global healthcare companies and CROs, providing systems and supporting services to 600+ clinical trial projects.